| Literature DB >> 26485279 |
Chun Xu1, Peijun Tang2, Cheng Ding1, Chang Li1, Jun Chen1, Zhenlei Xu1, Yi Mao1, Meiying Wu2, Jun Zhao1.
Abstract
BACKGROUND: Vitamin D receptor (VDR) gene FokI polymorphism have been studied in relation to tuberculosis (TB) in many populations and provided inconsistent results. In this study, we carried out a meta-analysis to derive a more reliable assessment on FokI polymorphism and the risk of HIV-negative TB.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26485279 PMCID: PMC4618110 DOI: 10.1371/journal.pone.0140634
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Scale for quality assessment.
| Criteria | Score |
|---|---|
| Representativeness of cases | |
| Selected from population or tuberculosis registry | 3 |
| Selected from hospital | 2 |
| Not described | 1 |
| Representativeness of controls | |
| Population-based | 3 |
| Blood donors or volunteers | 2 |
| Hospital-based(cancer-free patients) | 1 |
| Not described | 0 |
| Specimens of cases determining genotypes | |
| White blood cells or normal tissues | 3 |
| Tumor tissues or exfoliated cells of tissue | 0 |
| Hardy-Weinberg equilibrium in controls | |
| Hardy-Weinberg equilibrium | 3 |
| Hardy-Weinberg disequilibrium | 0 |
| Total sample size | |
| ≥1000 | 3 |
| ≥500 but <1000 | 2 |
| ≥200 but <500 | 1 |
| <200 | 0 |
Fig 1Flow diagram of included studies for this meta-analysis.
Characteristics of studies included in the meta-analysis.
| Study | Year | Country | Total sample | TB | Source of Control | Genotyping method | Cases sequence | Control sequence |
| Quality scores | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases | Control | F/F | F/f | f/f | F/F | F/f | f/f | ||||||||
| Alagarasu | 2009 | India | 105 | 144 | PTB | PB | SSP-PCR | 65 | 31 | 9 | 81 | 59 | 4 | 0.076 | 13 |
| Bobb | 2007 | South Africa | 352 | 249 | PTB | PB | RFLP-PCR | 203 | 129 | 20 | 132 | 104 | 13 | 0.192 | 13 |
| Banoei | 2010 | Iranian | 60 | 62 | PTB | PB | SSP-PCR | 30 | 21 | 9 | 29 | 27 | 6 | 0.937 | 11 |
| Liu | 2004 | China | 120 | 240 | PTB | PB | RFLP-PCR | 29 | 63 | 28 | 85 | 120 | 35 | 0.482 | 12 |
| Lombard | 2006 | South Africa | 104 | 117 | PTB,MTB | HB | SSP-PCR | 68 | 33 | 3 | 90 | 24 | 3 | 0.373 | 11 |
| Roth | 2004 | Peru | 100 | 100 | PTB | HB | RFLP-PCR | 9 | 32 | 59 | 7 | 36 | 57 | 0.689 | 11 |
| SALIMI | 2015 | Iran | 120 | 131 | PTB | HB | RFLP-PCR | 65 | 44 | 11 | 93 | 31 | 7 | 0.054 | 12 |
| Selvaraj | 2008 | India | 51 | 60 | PTB | PB | RFLP-PCR | 31 | 16 | 4 | 27 | 33 | 0 | 0.003 | 8 |
| Selvaraj | 2009 | India | 65 | 60 | PTB | PB | RFLP-PCR | 33 | 29 | 3 | 33 | 26 | 1 | 0.102 | 11 |
| Sinaga | 2014 | Indonesia | 76 | 76 | PTB | HB | RFLP-PCR | 27 | 42 | 7 | 30 | 34 | 12 | 0.650 | 11 |
| Singh | 2011 | East india | 101 | 225 | PTB | HB | RFLP-PCR | 55 | 40 | 6 | 96 | 110 | 19 | 0.107 | 11 |
| Wilkinson | 2000 | UK | 91 | 116 | TB | HB | RFLP-PCR | 52 | 31 | 8 | 74 | 39 | 3 | 0.418 | 11 |
| Wu | 2013 | China | 213 | 211 | PTB | HB | RFLP-PCR | 72 | 96 | 45 | 101 | 88 | 22 | 0.664 | 11 |
| Zhang | 2010 | China | 110 | 102 | spinal-TB | HB | RFLP-PCR | 16 | 43 | 51 | 26 | 47 | 29 | 0.433 | 11 |
PB, Population—based; HB, Hospital—based; PTB, pulmonary tuberculosis; MTB, meningeal tuberculosis; SSP-PCR, sequence specific primer-polymerase chain reaction; RFLP-PCR, polymerase chain reaction-restriction fragment length polymorphism; HWE, Hardy—Weinberg equilibrium in control population
Meta-analysis of FOKI Polymorphism and HIV-negative TB risk.
| Comparison | Group | No. of studies | Test of association | Heterogeneity | |||
|---|---|---|---|---|---|---|---|
| OR | 95%CI |
| I2% |
| |||
|
| overall | 14 | 1.69 | 1.19–2.41 | 0.004 | 39.5 | 0.064 |
|
| overall | 14 | 1.06 | 0.83–1.35 | 0.623 | 57.8 | 0.004 |
|
| overall | 14 | 1.48 | 1.13–1.95 | 0.005 | 19.6 | 0.240 |
|
| |||||||
| overall | 14 | 1.60 | 1.28–1.97 | <0.001 | 29.5 | 0.141 | |
| Asian | 11 | 1.82 | 1.42–2.33 | <0.001 | 31.0 | 0.150 | |
| Africa | 2 | 1.10 | 0.57–2.12 | 0.778 | 0.0 | 0.974 | |
| SSP-PCR | 3 | 1.96 | 0.97–4.00 | 0.061 | 0.0 | 0.537 | |
| RFLP-PCR | 11 | 1.56 | 1.25–1.96 | <0.001 | 40.6 | 0.078 | |
| PTB | 11 | 1.48 | 1.16–1.89 | 0.001 | 34.4 | 0.123 | |
| HWE | 13 | 1.56 | 1.27–1.92 | <0.001 | 28.1 | 0.161 | |
| Score > 10 | 13 | 1.56 | 1.27–1.92 | <0.001 | 28.1 | 0.161 | |
| PB | 6 | 1.75 | 1.22–2.56 | 0.003 | 0.0 | 0.486 | |
| HB | 8 | 1.52 | 1.16–1.89 | 0.002 | 49.1 | 0.056 | |
PB, Population—based; HB, Hospital—based; PTB, pulmonary tuberculosis; MTB, meningeal tuberculosis; SSP-PCR, sequence specific primer-polymerase chain reaction; RFLP-PCR, polymerase chain reaction-restriction fragment length polymorphism; HWE, Hardy—Weinberg equilibrium in control population
Fig 2Forest plot of VDR FokI Polymorphism and HIV-negative TB risk in recessive model.
Fig 3Sensitivity analysis for VDR FokI Polymorphism and HIV-negative TB risk in recessive model.
This figure shows the influence of individual studies on the summary OR. The middle vertical axis indicates the overall OR and the two vertical axes indicate its 95% CI. Every hollow round indicates the pooled OR when the left study is omitted in this meta-analysis. The two ends of every broken line represent the 95% CI.
Fig 4Begg’s funnel plot for contrast in overall analysis in recessive model.
Each point represents a separate study for the indicated association. Size graph symbol by weights. Log[OR] natural logarithm of OR. Horizontal line mean effect size.